R&D ranking of global medical companies released
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
- Kochi University pioneers outpatient bladder cancer treatment using semiconductor lasers
- ASPEN 2024: Nutritional Therapy Strategies for Cancer and Critically Ill Patients
- Which lung cancer patients can benefit from neoadjuvant immunotherapy?
- Heme Iron Absorption: Why Meat Matters for Women’s Iron Needs
- “Miracle Weight-loss Drug” Semaglutide Is Not Always Effective
R&D ranking of global medical companies released
R&D ranking of global medical companies released. On December 4, Medical Design & Outsourcing released the 2020 R&D ranking of global medical device companies. Among them, the top three are Medtronic, Philips and Johnson & Johnson.
The eternal Big Three
Medical Design & Outsourcing also previously released the list of the top 100 global medical device companies in 2020 (2020 BIG 100) and the list of the top ten medical device companies in the world.
1. Medtronic- 2. Johnson & Johnson
- 3. Royal Philips
- 4. GE Healthcare
- 5. Essilor Luxentica
- 6. Siemens Healthineers
- 7. Cardinal Health
- 8. Stryker
- 9. Medline Industries
- 10. Danaher
The list is ranked according to the annual revenue of each company’s medical device business in fiscal year 2019 (annual results released before June 30, 2020). Medtronic, Johnson & Johnson, and Philips continue to rank among the top three global medical device companies in terms of revenue.
It is worth mentioning that in the 2020 global medical device company R&D rankings, the top three are still Medtronic, Johnson & Johnson, and Philips.
What is the quarterly performance of the top three?
Medtronic, Inc.
Medtronic announced its results for the second quarter of fiscal 2021. During the reporting period, revenue was US$7.647 billion, compared with US$7.706 billion in the same period last year. Net profit was US$494 million, compared with US$1.371 billion in the same period last year.
By business, the minimally invasive treatment group’s revenue was US$2.285 billion, a year-on-year increase of 6.7%; the cardiovascular group’s revenue was US$2.725 billion, a year-on-year decrease of 4.6%; the recovery treatment group’s revenue was US$2.063 billion, a year-on-year decrease of 2.3% ; Diabetes group revenue was 574 million US dollars, down 3.7% year-on-year.
Johnson & Johnson
Johnson & Johnson’s performance in the third quarter of 2020 far exceeded expectations, with sales in the third quarter rising from US$20.729 billion in the same period last year to US$21.082 billion. Among them, the sales of medical device business was US$6.15 billion. Net profit rose to US$3.554 billion from US$1.753 billion in the same period last year, a year-on-year increase of 102.7%.
Philips
Philips announced its unaudited results for the third quarter of 2020. Sales were 4.98 billion euros (approximately 5.96 billion US dollars), an increase of 6% year-on-year.
Among them, the care and nursing business sales were 1.556 billion euros, an increase of 36% year-on-year; the personal health business sales were 1.376 billion euros, and the same period last year was 1.358 billion euros, a slight increase. Sales of the diagnosis and treatment business were 1.971 billion euros, a year-on-year decrease of 7%. Net profit was 340 million euros, a year-on-year increase of 63.5%.
